187 related articles for article (PubMed ID: 36401031)
1. Morpholino-Mediated Exons 28-29 Skipping of Dysferlin and Characterization of Multiexon-skipped Dysferlin using RT-PCR, Immunoblotting, and Membrane Wounding Assay.
Anwar S; Yokota T
Methods Mol Biol; 2023; 2587():183-196. PubMed ID: 36401031
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic exon skipping for dysferlinopathies?
Aartsma-Rus A; Singh KH; Fokkema IF; Ginjaar IB; van Ommen GJ; den Dunnen JT; van der Maarel SM
Eur J Hum Genet; 2010 Aug; 18(8):889-94. PubMed ID: 20145676
[TBL] [Abstract][Full Text] [Related]
3. DYSF mutation analysis in a group of Chinese patients with dysferlinopathy.
Zhao Z; Hu J; Sakiyama Y; Okamoto Y; Higuchi I; Li N; Shen H; Takashima H
Clin Neurol Neurosurg; 2013 Aug; 115(8):1234-7. PubMed ID: 23254335
[TBL] [Abstract][Full Text] [Related]
4. Exon 32 Skipping of Dysferlin Rescues Membrane Repair in Patients' Cells.
Barthélémy F; Blouin C; Wein N; Mouly V; Courrier S; Dionnet E; Kergourlay V; Mathieu Y; Garcia L; Butler-Browne G; Lamaze C; Lévy N; Krahn M; Bartoli M
J Neuromuscul Dis; 2015 Sep; 2(3):281-290. PubMed ID: 27858744
[TBL] [Abstract][Full Text] [Related]
5. Identification of Novel Antisense-Mediated Exon Skipping Targets in DYSF for Therapeutic Treatment of Dysferlinopathy.
Lee JJA; Maruyama R; Duddy W; Sakurai H; Yokota T
Mol Ther Nucleic Acids; 2018 Dec; 13():596-604. PubMed ID: 30439648
[TBL] [Abstract][Full Text] [Related]
6. Efficient bypass of mutations in dysferlin deficient patient cells by antisense-induced exon skipping.
Wein N; Avril A; Bartoli M; Beley C; Chaouch S; Laforêt P; Behin A; Butler-Browne G; Mouly V; Krahn M; Garcia L; Lévy N
Hum Mutat; 2010 Feb; 31(2):136-42. PubMed ID: 19953532
[TBL] [Abstract][Full Text] [Related]
7. Dysferlinopathies: Clinical and genetic variability.
Ivanova A; Smirnikhina S; Lavrov A
Clin Genet; 2022 Dec; 102(6):465-473. PubMed ID: 36029111
[TBL] [Abstract][Full Text] [Related]
8. Full-length dysferlin expression driven by engineered human dystrophic blood derived CD133+ stem cells.
Meregalli M; Navarro C; Sitzia C; Farini A; Montani E; Wein N; Razini P; Beley C; Cassinelli L; Parolini D; Belicchi M; Parazzoli D; Garcia L; Torrente Y
FEBS J; 2013 Dec; 280(23):6045-60. PubMed ID: 24028392
[TBL] [Abstract][Full Text] [Related]
9. Correction of pseudoexon splicing caused by a novel intronic dysferlin mutation.
Dominov JA; Uyan Ö; McKenna-Yasek D; Nallamilli BRR; Kergourlay V; Bartoli M; Levy N; Hudson J; Evangelista T; Lochmuller H; Krahn M; Rufibach L; Hegde M; Brown RH
Ann Clin Transl Neurol; 2019 Apr; 6(4):642-654. PubMed ID: 31019989
[TBL] [Abstract][Full Text] [Related]
10. Novel DYSF mutations in Thai patients with distal myopathy.
Liewluck T; Pongpakdee S; Witoonpanich R; Sangruchi T; Pho-Iam T; Limwongse C; Thongnoppakhun W; Boonyapisit K; Sopassathit V; Phudhichareonrat S; Suthiponpaisan U; Raksadawan N; Goto K; Hayashi YK; Nishino I
Clin Neurol Neurosurg; 2009 Sep; 111(7):613-8. PubMed ID: 19493611
[TBL] [Abstract][Full Text] [Related]
11. In Vitro Multiexon Skipping by Antisense PMOs in Dystrophic Dog and Exon 7-Deleted DMD Patient.
Nakamura A; Aoki Y; Tsoumpra M; Yokota T; Takeda S
Methods Mol Biol; 2018; 1828():151-163. PubMed ID: 30171540
[TBL] [Abstract][Full Text] [Related]
12. Dysferlin mutation analysis in a group of Italian patients with limb-girdle muscular dystrophy and Miyoshi myopathy.
Kawabe K; Goto K; Nishino I; Angelini C; Hayashi YK
Eur J Neurol; 2004 Oct; 11(10):657-61. PubMed ID: 15469449
[TBL] [Abstract][Full Text] [Related]
13. Dysferlin mutations in LGMD2B, Miyoshi myopathy, and atypical dysferlinopathies.
Nguyen K; Bassez G; Bernard R; Krahn M; Labelle V; Figarella-Branger D; Pouget J; Hammouda el H; Béroud C; Urtizberea A; Eymard B; Leturcq F; Lévy N
Hum Mutat; 2005 Aug; 26(2):165. PubMed ID: 16010686
[TBL] [Abstract][Full Text] [Related]
14. Designing Effective Antisense Oligonucleotides for Exon Skipping.
Shimo T; Maruyama R; Yokota T
Methods Mol Biol; 2018; 1687():143-155. PubMed ID: 29067661
[TBL] [Abstract][Full Text] [Related]
15. Reverse engineering gene network identifies new dysferlin-interacting proteins.
Cacciottolo M; Belcastro V; Laval S; Bushby K; di Bernardo D; Nigro V
J Biol Chem; 2011 Feb; 286(7):5404-13. PubMed ID: 21119217
[TBL] [Abstract][Full Text] [Related]
16. Translational research and therapeutic perspectives in dysferlinopathies.
Barthélémy F; Wein N; Krahn M; Lévy N; Bartoli M
Mol Med; 2011; 17(9-10):875-82. PubMed ID: 21556485
[TBL] [Abstract][Full Text] [Related]
17. Limb Girdle Muscular Dystrophy Type 2B (LGMD2B): Diagnosis and Therapeutic Possibilities.
Poudel BH; Fletcher S; Wilton SD; Aung-Htut M
Int J Mol Sci; 2024 May; 25(11):. PubMed ID: 38891760
[TBL] [Abstract][Full Text] [Related]
18. Tips to Design Effective Splice-Switching Antisense Oligonucleotides for Exon Skipping and Exon Inclusion.
Maruyama R; Yokota T
Methods Mol Biol; 2018; 1828():79-90. PubMed ID: 30171536
[TBL] [Abstract][Full Text] [Related]
19. Antisense-Mediated Skipping of Dysferlin Exons in Control and Dysferlinopathy Patient-Derived Cells.
Verwey N; Gazzoli I; Krause S; Mamchaoui K; Mouly V; Aartsma-Rus A
Nucleic Acid Ther; 2020 Apr; 30(2):71-79. PubMed ID: 31873062
[TBL] [Abstract][Full Text] [Related]
20. The Dysferlinopathies Conundrum: Clinical Spectra, Disease Mechanism and Genetic Approaches for Treatments.
Anwar S; Yokota T
Biomolecules; 2024 Feb; 14(3):. PubMed ID: 38540676
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
